Table 2.
Baseline demographic and disease characteristics of patients with PsA stratified by prior anti-TNF therapy
| Patients with PsA (N = 442) | ||||||||
|---|---|---|---|---|---|---|---|---|
| Prior TNF antagonist(s) | Reason for discontinuation of prior TNF antagonista | |||||||
| No prior ETN/IFX | Prior ETN and/or IFX | IFX only | ETN only | IFX and ETN | Lack of response | Loss of response | Intolerance | |
| Characteristic | (n = 376) | (n = 66) | (n = 18) | (n = 34) | (n = 14) | (n = 14) | (n = 29) | (n = 9) |
| Male (%) | 50 | 47 | 61 | 41 | 43 | 50 | 45 | 44 |
| Age (years; mean ± SD) | 48 ± 11 | 47 ± 12 | 44 ± 12 | 47 ± 13 | 50 ± 8 | 43 ± 10 | 48 ± 13 | 51 ± 11 |
| PsA duration (years; mean ± SD) | 10 ± 8 | 12 ± 8 | 13 ± 7 | 9 ± 8 | 17 ± 8 | 7 ± 5 | 14 ± 7 | 14 ± 11 |
| Psoriasis (%)b | 83 | 80 | 78 | 79 | 86 | 79 | 79 | 78 |
| Nail dystrophy (%)c | 59 | 55 | 72 | 41 | 64 | 43 | 62 | 11 |
| Concomitant DMARDs (%) | 71 | 52 | 72 | 35 | 64 | 29 | 59 | 44 |
| Concomitant glucocorticoids (%) | 26 | 44 | 44 | 41 | 50 | 36 | 41 | 44 |
| C-reactive protein (mg/dl)d | 0.9 | 1.3 | 0.8 | 1.5 | 1.1 | 0.8 | 1.6 | 1.4 |
| 0.4, 2.2 | 0.3, 2.8 | 0.1 to 8.4e | 0.1 to 7.0e | 0.5 to 4.7e | 0.1 to 7.0e | 0.1 to 8.4e | 0.2 to 3.4e | |
aNo additional reason except for "other." bPatients with PGA other than "Clear." cPatients with NAPSI score ≥ 1. dReference value, 0.4 mg/dl; values listed are median and quartile 1, quartile 3 because of skewed distribution. eRanges presented are minimum to maximum because of small numbers of patients per group. DMARDs, disease-modifying antirheumatic drug; ETN, etanercept; IFX, infliximab; NAPSI, nail psoriasis severity index; NSAID, nonsteroidal antiinflammatory drug; PGA, Physician's Global Assessment of psoriasis; PsA, psoriatic arthritis; TNF, tumor necrosis factor.